{"id":"NCT00763451","sponsor":"Sanofi","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2011-01","completion":"2011-01","firstPosted":"2008-10-01","resultsPosted":"2016-12-14","lastUpdate":"2016-12-14"},"enrollment":484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClikÂ®"]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Lixisenatide (Two-Step Titration)","type":"EXPERIMENTAL"},{"label":"Lixisenatide (One-Step Titration)","type":"EXPERIMENTAL"},{"label":"Placebo (Two-Step Titration)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo (One-Step Titration)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide when added to metformin on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction when it is used in two steps dose titration regimen at Week 24.\n\nSecondary objectives are to assess the effects of lixisenatide when added to metformin on glycemic control in comparison to placebo in terms of HbA1c reduction when it is used in a one-step dose titration regimen, the percentage of patients with HbA1c less than 7 percent or less than or equal to 6.5%, body weight, fasting plasma glucose (FPG); to assess the safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.","primaryOutcome":{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo (Combined)","deltaMin":-0.42,"sd":0.099},{"arm":"Lixisenatide (Two-Step Titration)","deltaMin":-0.83,"sd":0.099},{"arm":"Lixisenatide (One-Step Titration)","deltaMin":-0.92,"sd":0.101}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":26},"locations":{"siteCount":15,"countries":["United States","Brazil","Chile","Colombia","Estonia","Germany","Italy","Lithuania","Malaysia","Mexico","Philippines","Poland","Romania","Slovakia","Ukraine"]},"refs":{"pmids":["24117597","39963952","24236828"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":79},"commonTop":["Nausea","Headache","Diarrhoea","Nasopharyngitis","Dizziness"]}}